Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „ADCETRIS“
Suchtreffer
Begriffe & Kennungen
Adcetris · 4.5 · There were no formal drug-drug interaction studies with brentuximab vedotin and bleomycin (B). In a phase 1 do
Eintrag öffnenAdcetris · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenAdcetris · 4.8 Undesirable effects · 1
Eintrag öffnenAdcetris · 4.8 · 14 The safety data in patients retreated with ADCETRIS (SGN35-006, see section 5.1) were consistent with those
Eintrag öffnenAdcetris · 4.8 · 15 System organ class Adverse reactions (monotherapy) Adverse reactions (combination therapy) Not known: Progr
Eintrag öffnenAdcetris · 4.8 · 16 b. Toxic epidermal necrolysis was not reported in the combination therapy setting. c. Extravasation may res
Eintrag öffnenAdcetris · 4.8 · 17 Febrile neutropenia was reported in 20% of the patients who did not receive primary prophylaxis with G-CSF
Eintrag öffnenAdcetris · 4.8 · 18 peripheral neuropathy was 8 weeks. Patients who discontinued due to peripheral neuropathy received a median
Eintrag öffnenAdcetris · 4.8 · 19 persistently positive anti-drug antibodies (ADA) relative to patients with transiently positive ADA and nev
Eintrag öffnenAdcetris · 4.8 · Adverse events led to treatment discontinuation in 10% of patients. Adverse events that led to treatment disco
Eintrag öffnenAdcetris · 4.8 · Adverse events led to treatment discontinuation in 24% of patients receiving ADCETRIS.
Eintrag öffnenAdcetris · 4.8 · Adverse reactions for ADCETRIS are listed by MedDRA System Organ Class and Preferred Term (see Table 7). Withi
Eintrag öffnenAdcetris · 4.8 · Among patients who experienced peripheral neuropathy in the pivotal phase 2 studies (SG035-0003 and SG035-0004
Eintrag öffnenAdcetris · 4.8 · Among patients who experienced peripheral neuropathy, the median follow up time from end of treatment until la
Eintrag öffnenAdcetris · 4.8 · Among patients who experienced peripheral neuropathy, the median follow up time from end of treatment until la
Eintrag öffnenAdcetris · 4.8 · Combination Use Study C25004
Eintrag öffnenAdcetris · 4.8 · Combination therapy
Eintrag öffnenAdcetris · 4.8 · Combination therapy (AVD/CHP)
Eintrag öffnenAdcetris · 4.8 · Combination therapy (BrECADD regimen)
Eintrag öffnenAdcetris · 4.8 · Description of selected adverse reactions
Eintrag öffnen